PRECIGEN, INC. Cash and Restricted Cash
PRECIGEN, INC. (PGEN) had Cash and Restricted Cash of $16.33 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-04
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $16.33M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $7.48M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $30.23M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $14.32M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $16.33M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $7.48M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $30.23M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $14.32M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $13.76M 10-Q · filed 2026-08-04 |
| 2025-03-31 | $6.06M 10-Q · filed 2026-05-13 |
| 2024-12-31 | $29.52M 10-Q · filed 2026-08-04 |
| 2024-09-30 | $24.73M 10-Q · filed 2025-11-13 |
| 2024-06-30 | $9.61M 10-Q · filed 2025-08-12 |
| 2024-03-31 | $17.74M 10-Q · filed 2025-05-14 |
| 2023-12-31 | $7.85M 10-K · filed 2026-03-25 |
| 2023-09-30 | $10.34M 10-Q · filed 2024-11-14 |
| 2023-06-30 | $16.95M 10-Q · filed 2024-08-14 |
| 2023-03-31 | $23.95M 10-Q · filed 2024-05-14 |
| 2022-12-31 | $48.60M 10-K · filed 2026-03-25 |
| 2022-09-30 | $91.88M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $49.90M 10-Q · filed 2023-08-09 |
| 2022-03-31 | $40.73M 10-Q · filed 2023-05-10 |
| 2021-12-31 | $43.34M 10-K · filed 2025-03-19 |
| 2021-09-30 | $42.16M 10-Q · filed 2022-11-09 |
| 2021-06-30 | $36.85M 10-Q · filed 2022-08-08 |
| 2021-03-31 | $27.79M 10-Q · filed 2022-05-09 |
| 2020-12-31 | $52.25M 10-K · filed 2024-03-19 |
| 2020-09-30 | $28.18M 10-Q · filed 2021-11-08 |
| 2020-06-30 | $47.13M 10-Q · filed 2021-08-09 |
| 2020-03-31 | $38.25M 10-Q · filed 2021-05-10 |
| 2019-12-31 | $68.43M 10-K · filed 2023-03-06 |
| 2019-09-30 | $44.84M 10-Q · filed 2020-11-09 |
| 2019-06-30 | $58.59M 10-Q · filed 2020-08-10 |
| 2019-03-31 | $106.96M 10-Q · filed 2020-05-11 |
| 2018-12-31 | $110.18M 10-K · filed 2022-03-01 |
| 2018-09-30 | $89.84M 10-Q · filed 2019-11-12 |
| 2018-06-30 | $85.89M 10-Q · filed 2019-08-09 |
| 2018-03-31 | $127.38M 10-Q · filed 2019-05-09 |
| 2017-12-31 | $75.55M 10-K · filed 2021-03-01 |
| 2017-09-30 | $71.64M 10-Q · filed 2018-11-08 |
| 2017-06-30 | $71.77M 10-Q · filed 2018-08-13 |
| 2017-03-31 | $76.84M 10-Q/A · filed 2018-08-13 |
| 2016-12-31 | $69.59M 10-K · filed 2020-03-02 |
| 2015-12-31 | $135.78M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |